Evotec Establishes Research Collaboration With Harvard University and the Howard Hughes Medical Institute in Diabetes Research

Collaboration Established to Drive Innovation and Develop New Diabetes Therapies Targeting Beta Cell Regeneration

11-Mar-2011 - Germany

Evotec AG announced the establishment of a research collaboration with Harvard University and the Howard Hughes Medical Institute (HHMI) aimed at discovering and developing new treatments in the field of diabetes.

The initial goal of the collaboration is to pursue a comprehensive and systematic approach towards the identification and development of physiological mechanisms and targets that regulate beta cell replication. Harvard, HHMI, and Evotec bring together extensive expertise and know-how in beta cell biology and diabetes along with an unparalleled set of tools to exploit beta cell related mechanisms and targets. This unique collaboration will be fueled by substantial scientific contributions from Harvard and HHMI as well as Evotec's firm commitment to deliver on their common goal to develop orally available small molecule therapies that trigger or support beta cell replication.

Therapies that trigger/support beta cell replication are expected to enhance or even restore the body's ability to produce sufficient insulin to maintain optimal glycemic control and thereby reduce and prevent the development of diabetic complications. Leveraging key insights about beta cell replication and forming co-development alliances with pharmaceutical companies at the appropriate point in the development chain are the core strategic drivers of the collaboration.

Further details and commercial terms of the cooperation are not disclosed.

https://www.bionity.com/en/news/131286/evotec-establishes-research-collaboration-with-harvard-university-and-the-howard-hughes-medical-institute-in-diabetes-research.html